18:33 , Nov 30, 2018 |  BC Week In Review  |  Company News

Sinovant gains Chinese rights to Angion's BB3

Angion Biomedica Corp. (Uniondale, N.Y.) granted Sinovant Sciences Ltd. (Beijing, China) exclusive rights to develop, commercialize and manufacture BB3 in China, including Hong Kong and Macau, and Taiwan. Angion will receive an upfront payment and...
23:45 , Mar 31, 2017 |  BioCentury  |  Politics, Policy & Law

Balancing act

Scott Gottlieb’s toughest political challenge before and after confirmation as FDA commissioner will not be from a hostile Congress, but rather from White House officials who believe the agency is an impediment to medical progress...
20:16 , Feb 16, 2017 |  BC Week In Review  |  Clinical News

BB3: Ph II GUARD started

Angion began the double-blind, placebo-controlled, U.S. Phase II GUARD trial to evaluate 6 mg/mL IV BB3 daily for 4 days in about 100 patients who undergo open heart surgery and require the use of cardiopulmonary...
07:00 , Oct 27, 2014 |  BC Week In Review  |  Financial News

Angion withdraws IPO

Angion Biomedica Corp. , Uniondale, N.Y.   Business: Renal, Pulmonary   Date announced: 2014-10-24   Type: IPO   Underwriter: Aegis Capital   Note: Angion Biomedica withdrew its IPO on NASDAQ, citing market conditions.  ...
00:56 , Oct 25, 2014 |  BC Extra  |  Financial News

Angion withdraws IPO

Angion Biomedica Corp. (Uniondale, N.Y.) withdrew its proposed IPO on NASDAQ, citing market conditions. In June, the company amended its IPO to sell 2.7 million shares at $10-$12. At $11, the company would have raised...
07:00 , Oct 6, 2014 |  BioCentury  |  Finance

4Q14 Financial Markets Preview: 'Perfect world' - for now

Even as the major biotech indices creep toward new all-time highs, buysiders are hard-pressed to identify any major risks that could cause a downturn in the fourth quarter. At the same time, there are few...
07:00 , Jul 14, 2014 |  BioCentury  |  Finance

3Q14 Financial Markets Preview: Discerning optimism

Investors and bankers are cautiously optimistic that the correction that began in late 1Q14 will provide a floor for a biotech recovery that should continue through the third quarter, with investors being more selective on...
07:00 , Jun 2, 2014 |  BC Week In Review  |  Financial News

Angion amends IPO

Angion Biomedica Corp. , Uniondale, N.Y.   Business: Renal, Pulmonary   Date announced: 5/23/14   Type: IPO   To be raised: Up to $32.7 million   Shares: 2.7 million   Price: $10-$12   Underwriter: Aegis...
01:23 , May 28, 2014 |  BC Extra  |  Financial News

Angion sets IPO terms

Angion Biomedica Corp. (Uniondale, N.Y.) amended its IPO on NASDAQ and now plans to sell 2.7 million shares at $10-$12. At the $11 midpoint, the company would raise $30 million and be valued at $73.1...
07:00 , Apr 21, 2014 |  BC Week In Review  |  Financial News

Angion proposes IPO

Angion Biomedica Corp. , Uniondale, N.Y.   Business: Renal, Pulmonary   Date announced: 4/14/14   Type: IPO   To be raised: Up to $34.5 million   Shares: TBD   Price: TBD   Underwriter: Aegis Capital...